Cargando…
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA admin...
Autores principales: | Kawagishi, Naoki, Suda, Goki, Yamamoto, Yoshiya, Baba, Masaru, Furuya, Ken, Maehara, Osamu, Ohnishi, Shunsuke, Yoshida, Sonoe, Fu, Qingjie, Yang, Zijian, Hosoda, Shunichi, Tokuchi, Yoshimasa, Kitagataya, Takashi, Ohara, Masatsugu, Suzuki, Kazuharu, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Ogawa, Koji, Sakamoto, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862289/ https://www.ncbi.nlm.nih.gov/pubmed/36680221 http://dx.doi.org/10.3390/v15010181 |
Ejemplares similares
-
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2023) -
Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma
por: Ohara, Masatsugu, et al.
Publicado: (2023) -
Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Tokuchi, Yoshimasa, et al.
Publicado: (2021) -
Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia
por: Yoshida, Sonoe, et al.
Publicado: (2021) -
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2022)